Insider trade

Pfizer (PFE): Director received 1,386.83 units

Cyrus Taraporevala, Director at Pfizer, reported a grant / award of 1,386.83 units.

1,386.83
Derivative units · @ $27.04
Traded
Mar 27, 2026
Filed
Mar 31, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Jan 26, 2026Federal contract · $9K obligatedDepartment of Defense awarded Pfizer: $9K obligated to date
  2. Jan 29, 2026Federal contract · $3K obligatedDepartment of Defense awarded Pfizer: $2.8K obligated to date
  3. Feb 3, 2026Company filing · Form 8-K · ResultsReported its results
  4. Feb 9, 2026Government · Federal Register ruleAir Plan Approval; Connecticut; Revised Format for Materials Incorporated by Reference
  5. Feb 10, 2026CongressDisclosed purchase of PFE — reported range $1,001 - $15,000
  6. Feb 18, 2026Federal contract · $8K obligatedDepartment of Defense awarded Pfizer: $8.2K obligated to date
  7. Feb 19, 2026Government · Federal Register noticeGranting of Requests for Early Termination of the Waiting Period Under the Premerger Notification Rules
  8. Feb 24, 2026FDAFDA drug approval: Braftovi
  9. Feb 24, 2026FDAFDA drug approval: Braftovi
  10. Feb 26, 2026Government · Federal Register noticeDetermination of Regulatory Review Period for Purposes of Patent Extension; ORLYNVAH
  11. Mar 6, 2026FDAFDA drug approval: Xeljanz
  12. Mar 6, 2026FDAFDA drug approval: Xeljanz XR
  13. Mar 9, 2026Government · Federal Register noticeAspen Global Inc. c/o Lachman Consultant Services, Inc., et al.; Withdrawal of Approval of 46 New Drug Applications
  14. Mar 13, 2026CongressDisclosed partial sale of PFE — reported range $1,001 - $15,000
  15. Mar 24, 2026CongressDisclosed sale of PFE — reported range $50,001 - $100,000
  16. Mar 27, 20265% stakeThe Vanguard Group reported a passive stake (13G)

What came next

  1. Apr 3, 2026Government · Federal Register noticeDetermination of Regulatory Review Period for Purposes of Patent Extension; HYMPAVZI
  2. Apr 8, 2026Federal contract · $15K obligatedDepartment of Defense awarded Pfizer: $15K obligated to date
  3. Apr 23, 2026Federal contract · $23K obligatedDepartment of Defense awarded Pfizer: $23K obligated to date
  4. Apr 23, 2026Federal contract · $2K obligatedDepartment of Defense awarded Pfizer: $2.2K obligated to date
  5. May 1, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.5%
  6. May 5, 2026Company filing · Form 8-K · ResultsReported its results
  7. May 13, 2026Federal contract · $25K obligatedDepartment of Defense awarded Pfizer: $25K obligated to date
  8. May 15, 2026Federal contract · $543K obligatedDepartment of Health and Human Services awarded Pfizer: $543K obligated to date
  9. May 20, 2026Federal contract · $2K obligatedDepartment of Defense awarded Pfizer: $2.2K obligated to date
  10. Jun 5, 2026FDAFDA drug approval: Hympavzi
  11. Jun 8, 2026Government · Federal Register noticeDetermination That Protamine Sulfate (Protamine Sulfate) Intravenous; Solution, 50 Milligrams/5 Milliliters, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
  12. Jun 8, 2026CongressDisclosed sale of PFE — reported range $15,001 - $50,000
  13. Jun 9, 2026InsiderOfficer sold ~$51K of PFE shares in the open market
  14. Jun 18, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On June 16, 2026, Dave Denton notified Pfizer Inc. (the “Company”) that he will step down from his current position as Chief Financial Officer effective August 15, 2026 for a professional opportunity outside of the pharmaceutical industry in consumer goods, and that his departure is not related to the Company’s financial or operating results or to any disagreements with the Company regarding the Company’s financial,…”
  15. Jun 24, 2026FDAFDA drug approval: Ibrance
  16. Jun 24, 2026FDAFDA drug approval: Ibrance
  17. Jul 6, 2026Government · Federal Register noticeEndo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
  18. Jul 15, 2026Federal contract · $5K obligatedDepartment of Defense awarded Pfizer: $4.9K obligated to date
  19. Jul 20, 2026Government · Federal Register noticeForeign-Trade Zone (FTZ) 43, Notification of Proposed Production Activity; Pfizer Inc.; (Pharmaceutical Products); Kalamazoo and Portage, Michigan
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Pfizer

For Pfizer, OQRO holds 1 fund holdings report (13F) and 1 federal contract award dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its PFE page.

How this filing works

Explore the data

Common questions

Which Pfizer (PFE) insider traded, and how much?

Cyrus Taraporevala, Director at Pfizer, reported a grant / award of 1,386.83 units. At $27.04.

When did it happen, and when was it made public?

Traded: Mar 27, 2026. Filed: Mar 31, 2026. That is 4 days between the two dates.

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Pfizer recently?

For Pfizer, OQRO holds 1 fund holdings report (13F) and 1 federal contract award dated in the last 90 days. They are listed on the PFE page.

Does this mean PFE stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Pfizer

Everything OQRO holds on this company is on its PFE page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data